Literature DB >> 22248521

Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure.

Mario I Fernández1, J Francisco López, Bruno Vivaldi, Fernando Coz.   

Abstract

PURPOSE: In this study we assessed bladder cancer health care and mortality trends in recent decades in a well studied arsenic exposed area in Northern Chile.
MATERIALS AND METHODS: Arsenic levels in the affected region were obtained for the last 60 years, and correlated with bladder cancer hospital discharge and mortality rates in recent decades.
RESULTS: Bladder cancer hospital discharge rates were significantly higher in the affected region (peak RR 3.6, 95% CI 3.0-4.7). Mortality rates for bladder cancer showed a trend of increase during the period analyzed, reaching peak mortality rates of 28.4 per 100,000 for men and 18.7 per 100,000 for women in the last 10 years. Poisson regression models showed an increased mortality risk in the studied region compared to the rest of the country until the present for men (IRR 5.3, 95% CI 4.8-5.8) and women (IRR 7.8, 95% CI 7.0-8.7). Mean age at cancer specific death was significantly lower in the exposed region (69.6 years, 95% CI 68.4-70.7 vs 73.7 years, 95% CI 73.3-74.2, p <0.01).
CONCLUSIONS: Exposure to arsenic is related to a significant need for bladder cancer health care and to high mortality rates even 20 years after having controlled arsenic levels in drinking water. Affected individuals should be aware of the significant impact of this ecological factor. Further research is required to identify strategies for the management of bladder cancer in arsenic exposed populations.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22248521     DOI: 10.1016/j.juro.2011.10.157

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

Review 1.  Bladder cancer in 2012: Challenging current paradigms.

Authors:  Aidan P Noon; James W F Catto
Journal:  Nat Rev Urol       Date:  2013-01-08       Impact factor: 14.432

2.  Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.

Authors:  Chien-Lun Chen; Ting Chung; Chih-Ching Wu; Kwai-Fong Ng; Jau-Song Yu; Cheng-Han Tsai; Yu-Sun Chang; Ying Liang; Ke-Hung Tsui; Yi-Ting Chen
Journal:  Mol Cell Proteomics       Date:  2015-06-16       Impact factor: 5.911

3.  Arsenic and lung disease mortality in Bangladeshi adults.

Authors:  Maria Argos; Faruque Parvez; Mahfuzar Rahman; Muhammad Rakibuz-Zaman; Alauddin Ahmed; Samar Kumar Hore; Tariqul Islam; Yu Chen; Brandon L Pierce; Vesna Slavkovich; Christopher Olopade; Muhammad Yunus; John A Baron; Joseph H Graziano; Habibul Ahsan
Journal:  Epidemiology       Date:  2014-07       Impact factor: 4.822

Review 4.  Arsenic and human health: epidemiologic progress and public health implications.

Authors:  Maria Argos; Habibul Ahsan; Joseph H Graziano
Journal:  Rev Environ Health       Date:  2012-09-10       Impact factor: 3.458

5.  Baseline comorbidities in a skin cancer prevention trial in Bangladesh.

Authors:  Maria Argos; Mahfuzar Rahman; Faruque Parvez; James Dignam; Tariqul Islam; Iftekhar Quasem; Samar K Hore; Ahmed T Haider; Zahid Hossain; Tazul I Patwary; Muhammad Rakibuz-Zaman; Golam Sarwar; Paul La Porte; Judith Harjes; Kristen Anton; Muhammad G Kibriya; Farzana Jasmine; Rashed Khan; Mohammed Kamal; Christopher R Shea; Muhammad Yunus; John A Baron; Habibul Ahsan
Journal:  Eur J Clin Invest       Date:  2013-04-17       Impact factor: 4.686

6.  The epigenetic effects of a high prenatal folate intake in male mouse fetuses exposed in utero to arsenic.

Authors:  Verne Tsang; Rebecca C Fry; Mihai D Niculescu; Julia E Rager; Jesse Saunders; David S Paul; Steven H Zeisel; Michael P Waalkes; Miroslav Stýblo; Zuzana Drobná
Journal:  Toxicol Appl Pharmacol       Date:  2012-08-31       Impact factor: 4.219

7.  Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.

Authors:  Domingo A Román; Isabel Pizarro; Lidia Rivera; Carolina Torres; Juan Avila; Pedro Cortés; Marjorie Gill
Journal:  BMC Res Notes       Date:  2012-04-30

8.  The use of regenerative medicine in the management of invasive bladder cancer.

Authors:  Matthew E Hyndman; Deborah Kaye; Nicholas C Field; Keith A Lawson; Norm D Smith; Gary D Steinberg; Mark P Schoenberg; Trinity J Bivalacqua
Journal:  Adv Urol       Date:  2012-08-27

9.  Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies.

Authors:  Zhaowei Zhu; Xiaohua Zhang; Zhoujun Shen; Shan Zhong; Xianjin Wang; Yingli Lu; Chen Xu
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  Bladder cancer: a simple model becomes complex.

Authors:  Giovanni Battista Di Pierro; Caterina Gulia; Cristiano Cristini; Giorgio Fraietta; Lorenzo Marini; Pietro Grande; Vincenzo Gentile; Roberto Piergentili
Journal:  Curr Genomics       Date:  2012-08       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.